{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T12:23:19Z","timestamp":1774959799600,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Bayer HealthCare Pharmaceuticals"},{"name":"Janssen Scientific Affairs, LLC"}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.ejim.2014.05.017","type":"journal-article","created":{"date-parts":[[2014,6,25]],"date-time":"2014-06-25T09:47:22Z","timestamp":1403689642000},"page":"600-606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups"],"prefix":"10.1016","volume":"25","author":[{"given":"Rupert M.","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2014.05.017_bb0005","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-0037-1613887","article-title":"Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale","volume":"83","author":"Oger","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11586730-000000000-00000","article-title":"Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment","volume":"28","author":"Samama","year":"2011","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ejim.2014.05.017_bb0015","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/eurheartj\/ehn310","article-title":"Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)","volume":"29","author":"Torbicki","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2014.05.017_bb0020","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2014.05.017_bb0025","first-page":"1046","article-title":"Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE)","volume":"91","author":"L\u00f3pez-Jim\u00e9nez","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2014.05.017_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjmed.2012.09.021","article-title":"Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function","volume":"126","author":"Trujillo-Santos","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1741-7015-10-4","article-title":"Frailty in primary care: a review of its conceptualization and implications for practice","volume":"10","author":"Lacas","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.ejim.2014.05.017_bb0045","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0050","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1538-7836.2005.01304.x","article-title":"The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)","volume":"3","author":"Barba","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0055","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-144-9-200605020-00011","article-title":"Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency","volume":"144","author":"Lim","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0060","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-06-096545","article-title":"Venous thrombosis in the elderly: more questions than answers","volume":"110","author":"Silverstein","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2014.05.017_bb0065","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1681\/ASN.2008070802","article-title":"Kidney function influences warfarin responsiveness and hemorrhagic complications","volume":"20","author":"Limdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0070","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.amjmed.2006.04.028","article-title":"Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry","volume":"119","author":"Monreal","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/j.1538-7836.2010.03986.x","article-title":"Venous thrombosis in the elderly: incidence, risk factors and risk groups","volume":"8","author":"Engbers","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0080","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1538-7836.2007.02507.x","article-title":"Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice","volume":"5","author":"Cook","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","article-title":"Warfarin: almost 60years old and still causing problems","volume":"62","author":"Pirmohamed","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ejim.2014.05.017_bb0095","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0149-2918(04)90187-7","article-title":"Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting","volume":"26","author":"Willey","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.ejim.2014.05.017_bb0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0105","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5694\/j.1326-5377.2009.tb02453.x","article-title":"The direct factor Xa inhibitor rivaroxaban","volume":"190","author":"Verma","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.ejim.2014.05.017_bb0115","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1007\/BF03022258","article-title":"Perioperative management of patients receiving vitamin K antagonists","volume":"53","author":"Ickx","year":"2006","journal-title":"Can J Anaesth"},{"key":"10.1016\/j.ejim.2014.05.017_bb0120","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.1997.00440430038005","article-title":"Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis","volume":"157","author":"Hull","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0125","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/pgmj.2007.059188","article-title":"Heparin induced thrombocytopenia: diagnosis and management update","volume":"83","author":"Ahmed","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ejim.2014.05.017_bb0130","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1378\/chest.130.3.681","article-title":"How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia?","volume":"130","author":"Levine","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2014.05.017_bb0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b819896a","article-title":"Lessons learned from the contamination of heparin","volume":"26","author":"Liu","year":"2009","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.ejim.2014.05.017_bb0140","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/ph3123543","article-title":"Anticoagulation in the elderly","volume":"3","author":"Robert-Ebadi","year":"2010","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejim.2014.05.017_bb0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0150","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1378\/chest.127.6.2049","article-title":"Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population","volume":"127","author":"Garcia","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2014.05.017_bb0155","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archinte.1996.00440080047006","article-title":"Aging and heparin-related bleeding","volume":"156","author":"Campbell","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0160","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/ki.2008.319","article-title":"The aging kidney","volume":"74","author":"Zhou","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2014.05.017_bb0165","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.18553\/jmcp.2011.17.7.523","article-title":"Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic","volume":"17","author":"Kleinow","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.ejim.2014.05.017_bb0175","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2174\/157016111797484170","article-title":"Low molecular weight heparins and glomerular filtration rate: a report to be considered","volume":"9","author":"Fabbian","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2165\/00002018-200528040-00005","article-title":"Safety profile of different low-molecular weight heparins used at therapeutic dose","volume":"28","author":"Gouin-Thibault","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.ejim.2014.05.017_bb0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MCP.0b013e328216430d","article-title":"Low molecular weight heparin and bleeding in patients with chronic renal failure","volume":"13","author":"Crowther","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2011.03.002","article-title":"Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep\u00ae in Renal Insufficiency Study (IRIS)","volume":"128","author":"Leizorovicz","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.ejim.2014.05.017_bb0195","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","article-title":"No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy","volume":"9","author":"Siguret","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0200","author":"Bayer Pharma AG"},{"key":"10.1016\/j.ejim.2014.05.017_bb0205","author":"Boehringer Ingelheim International GmbH"},{"key":"10.1016\/j.ejim.2014.05.017_bb0210","author":"Bristol-Myers Squibb"},{"key":"10.1016\/j.ejim.2014.05.017_bb0215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/FJC.0b013e31826265b6.","article-title":"Pharmacokinetics of the direct Factor Xa inhibitor edoxaban and digoxin administered alone and in combination","volume":"60","author":"Mendell","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0220","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00228-013-1510-z","article-title":"Novel oral anticoagulants: clinical pharmacology, indications and practical considerations","volume":"69","author":"Harder","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2014.05.017_bb0225","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ejim.2012.10.001","article-title":"New anticoagulants for treatment of venous thromboembolism","volume":"23","author":"Franchini","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0230","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","article-title":"Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral Factor Xa inhibitor","volume":"13","author":"Mendell","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.ejim.2014.05.017_bb0235","author":"Bristol-Myers Squibb"},{"key":"10.1016\/j.ejim.2014.05.017_bb0240","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0245","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0250","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"The Hokusai-VTE Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0255","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.05.017_bb0260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ejim.2014.05.017_bb0265","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0270","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0275","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1056\/NEJMc1112874","article-title":"Bleeding risk with dabigatran in the frail elderly","volume":"366","author":"Harper","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0280","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/j.1538-7836.2011.04507.x","article-title":"External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?","volume":"9","author":"Beyer-Westendorf","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0285","doi-asserted-by":"crossref","first-page":"e7498","DOI":"10.1136\/bmj.e7498","article-title":"Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials","volume":"345","author":"Fox","year":"2012","journal-title":"Br Med J"},{"key":"10.1016\/j.ejim.2014.05.017_bb0290","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0295","first-page":"439","article-title":"Chronic VTE treatment VTE with rivaroxaban. Updated results of the prospective Dresden NOAC registry (NCT01588119)","volume":"11","author":"Beyer-Westendorf","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2014.05.017_bb0300","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0305","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.05.017_bb0310","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1161\/CIRCULATIONAHA.112.001139","article-title":"The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study","volume":"128","author":"Connolly","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2014.05.017_bb0315","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051400154X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362051400154X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T07:12:15Z","timestamp":1649488335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362051400154X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S095362051400154X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2014.05.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2014.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}